Effect of Systemically Used Anti-Tumor Necrosis Factor-α Medication on the Corneal Epithelium and Stroma of Patients with Ankylosing Spondylitis

REFERENCES

• Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002; 14:337–341.
   PubMed Web of Science ®Google Scholar
• Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004; 20:155–157.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol. 2002;20:S143–145.
   PubMed Web of Science ®Google Scholar
• Matsuda J, Kaburaki T, Kobayashi S, et al. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis. Jpn J Ophthalmol. 2013;57:104–107.
   PubMed Web of Science ®Google Scholar
• Saika S. Yin and yang in cytokine regulation of corneal wound healing: roles of TNF-alpha. Cornea. 2007;26:S70–74.
   PubMed Web of Science ®Google Scholar
• Ortak H, Inanir A, Demir S, et al. Decreased central corneal thickness in ankylosing spondylitis. Int Ophthalmol. 2014;34:263–268.
   PubMed Web of Science ®Google Scholar
• Williamson JS, DiMarco S, Streilein JW. Immunobiology of Langerhans cells on the ocular surface. I. Langerhans cells within the central cornea interfere with induction of anterior chamber associated immune deviation. Invest Ophthalmol Vis Sci. 1987;28:1527–1532.
   PubMed Web of Science ®Google Scholar
• Marsovszky L, Németh J, Resch MD. Corneal Langerhans cell and dry eye examinations in ankylosing spondylitis. Innate Immun. 2013;20:471–477.
   PubMed Web of Science ®Google Scholar
• Katami M, Graudenz MS, White DJG, et al. The role of antigen-presenting cells in rat corneal graft rejection. Transplant Proc. 1991;23:93–95.
   PubMed Web of Science ®Google Scholar
• Gillette TE, Chandler JW, Greiner JV. Langerhans cells of the ocular surface. Ophthalmology. 1982;89:700–711.
   PubMed Web of Science ®Google Scholar
• Dekaris I, Zhu SN, Dana MR. TNF-alpha regulates corneal Langerhans cell migration. J Immunol. 1999;162:4235–4239.
   PubMed Web of Science ®Google Scholar
• Li DQ, Shang TY, Kim HS, et al. Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2003;44:2928–2936.
   PubMed Web of Science ®Google Scholar
• Francoz M, Karamoko I, Baudouin C, et al. Ocular surface epithelial thickness evaluation with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52:9116–9123.
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–2291.
   PubMed Web of Science ®Google Scholar
• Cui X, Hong J, Wang F, et al. Assessment of corneal epithelial thickness in dry eye patients. Optom Vis Sci. 2014;91:1446–1454.
   PubMed Web of Science ®Google Scholar
• Kanellopoulos AJ, Asimellis G. In vivo 3-dimensional corneal epithelial thickness mapping as an indicator of dry eye: preliminary clinical assessment. Am J Ophthalmol. 2014;157:63–68.
   PubMed Web of Science ®Google Scholar
• Villani E, Galimberti D, Viola F, et al. Corneal involvement in rheumatoid arthritis: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2008;49:560–564.
   PubMed Web of Science ®Google Scholar
• Cingü AK, Cınar Y, Türkcü FM, et al. Evaluation of corneal parameters with scheimpflug imaging in patients with rheumatoid arthritis. Ocul Immunol Inflamm. 2013;21:360–365.
   PubMed Web of Science ®Google Scholar
• Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res. 2000;5:507–511.
   PubMedGoogle Scholar
• Kobayashi Y. Langerhans’ cells produce type IV collagenase (MMP-9) following epicutaneous stimulation with haptens. Immunology. 1997;90:496–501.
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Doshi A, Farley W, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293–4301.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665–670.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Tan MH, Chen SD, Rubinstein A, et al. Corneal perforation due to severe peripheral ulcerative keratitis in Crohn disease. Cornea. 2006;25:628–630.
   PubMed Web of Science ®Google Scholar
• Spraul CW, Buchwald HJ, Lang GK, et al. [Recurrent corneal ulcer in a patient with Crohn’s disease associated with epidermolysis bullosa acquisita]. Klin Monbl Augenheilkd. 2003;220:423–426.
   PubMed Web of Science ®Google Scholar
• Schulman MF, Sugar A. Peripheral corneal infiltrates in inflammatory bowel disease. Ann Ophthalmol. 1981;13:109–111.
   PubMedGoogle Scholar
• Pham M, Chow CC, Badawi D, et al. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease. Am J Ophthalmol. 2011;152:183–188.
   PubMed Web of Science ®Google Scholar
• Kim HS, Shang T, Chen Z, et al. TGF-beta1 stimulates production of gelatinase (MMP-9), collagenases (MMP-1, -13) and stromelysins (MMP-3, -10, -11) by human corneal epithelial cells. Exp Eye Res. 2004;79:263–274.
   PubMed Web of Science ®Google Scholar
• Arends S, van der Veer E, Groen H, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol. 2011; 38:1644–1650.
   PubMed Web of Science ®Google Scholar
• Di Pascuale MA, Whitson JT, Mootha VV. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye Contact Lens. 2008;34:129–130.
   PubMed Web of Science ®Google Scholar
• Alvarez MT, Figueroa MS, Teus MA. Toxic keratolysis from combined use of nonsteroid anti-inflammatory drugs and topical steroids following vitreoretinal surgery. Eur J Ophthalmol. 2006;16:582–587.
   PubMed Web of Science ®Google Scholar
• Gabison EE, Chastang P, Menashi S, et al. Late corneal perforation after photorefractive keratectomy associated with topical diclofenac: involvement of matrix metalloproteinases. Ophthalmology. 2003; 110:1626–1631.
   Google Scholar
• Reviglio VE, Rana TS, Li QJ, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg. 2003;29:989–997.
   PubMed Web of Science ®Google Scholar
• Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936–944.
   PubMed Web of Science ®Google Scholar
• Masuda I, Matsuo T, Okamoto K, et al. Two cases of corneal perforation after oral administration of nonsteroidal anti-inflammatory drugs: oral NSAID-induced corneal damage. Eur J Ophthalmol. 2010;20:454–456.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin KC, Yu DT, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology. 2006;45:414–420.
   PubMed Web of Science ®Google Scholar